欧林生物
(688319)
| 流通市值：92.88亿 | | | 总市值：93.00亿 |
| 流通股本：4.05亿 | | | 总股本：4.06亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 305,849,689.82 | 87,490,281.98 | 588,858,464.45 | 386,646,898.48 |
| 营业收入 | 305,849,689.82 | 87,490,281.98 | 588,858,464.45 | 386,646,898.48 |
| 二、营业总成本 | 267,455,854.27 | 103,562,135.21 | 569,996,827.89 | 379,815,023.64 |
| 营业成本 | 20,889,102.06 | 5,748,186.46 | 32,707,434.85 | 20,425,109.52 |
| 税金及附加 | 2,477,746.03 | 512,277.03 | 3,716,416.72 | 2,226,976.66 |
| 销售费用 | 145,278,282.45 | 41,886,928.76 | 302,899,962.16 | 185,241,304.11 |
| 管理费用 | 32,902,561.01 | 22,743,811.47 | 86,424,382.85 | 63,044,731.6 |
| 研发费用 | 58,777,526.47 | 29,123,911.81 | 134,233,724.19 | 99,399,717.64 |
| 财务费用 | 7,130,636.25 | 3,547,019.68 | 10,014,907.12 | 9,477,184.11 |
| 其中:利息费用 | 7,455,488.08 | 3,719,578.74 | 14,283,986.99 | 10,383,811.72 |
| 其中:利息收入 | 425,415.39 | 229,609.01 | 4,508,119.26 | 1,101,681.82 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 150,511.64 | 70,592.05 | 855,559.79 | 500,625.69 |
| 资产处置收益 | 8,707.5 | - | -30,988.3 | - |
| 资产减值损失(新) | 491,601.37 | 1,271,436.02 | 2,936,350.79 | 5,074,024.15 |
| 信用减值损失(新) | -31,837,465.84 | 3,388,796.25 | -10,375,765.79 | -15,589,377.17 |
| 其他收益 | 7,484,305.7 | 4,297,791.76 | 9,063,439.56 | 3,702,801 |
| 四、营业利润 | 14,691,495.92 | -7,043,237.15 | 21,310,232.61 | 519,948.51 |
| 加:营业外收入 | 5,958.53 | 1,703.81 | 1,140,439.08 | 1,044,193.66 |
| 减:营业外支出 | 14,669.24 | - | 146,971.33 | 116,871.33 |
| 五、利润总额 | 14,682,785.21 | -7,041,533.34 | 22,303,700.36 | 1,447,270.84 |
| 减:所得税费用 | 1,452,994.79 | - | 6,583,013.04 | 1,530,181.21 |
| 六、净利润 | 13,229,790.42 | -7,041,533.34 | 15,720,687.32 | -82,910.37 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 13,229,790.42 | -7,041,533.34 | 15,720,687.32 | -82,910.37 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 13,196,891.47 | -7,073,911.78 | 20,757,584.86 | 4,025,906.59 |
| 少数股东损益 | 32,898.95 | 32,378.44 | -5,036,897.54 | -4,108,816.96 |
| 扣除非经常损益后的净利润 | 7,723,574.58 | -11,022,704.59 | 11,180,820.89 | -332,098.12 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | -0.02 | 0.05 | 0.01 |
| (二)稀释每股收益 | 0.03 | -0.02 | 0.05 | 0.01 |
| 九、综合收益总额 | 13,229,790.42 | -7,041,533.34 | 15,720,687.32 | -82,910.37 |
| 归属于母公司股东的综合收益总额 | 13,196,891.47 | -7,073,911.78 | 20,757,584.86 | 4,025,906.59 |
| 归属于少数股东的综合收益总额 | 32,898.95 | 32,378.44 | -5,036,897.54 | -4,108,816.96 |
| 公告日期 | 2025-08-29 | 2025-04-26 | 2025-03-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |